Immutep
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The last earnings update was 82 days ago. More info.
Add to Portfolio Compare Print
- Immutep has significant price volatility in the past 3 months.
IMM Share Price and Events
7 Day Returns
1 Year Returns
IMM Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Immutep (IMM) | 0% | 3.7% | -9.7% | 0% | -37.8% | -44% |
| AU Biotechs | 4.9% | 8.7% | 11.3% | 13.8% | 79.6% | 169% |
| AU Market | 1.1% | 1.6% | 4.1% | 2.6% | 17.9% | 7.7% |
1 Year Return vs Industry and Market
- IMM underperformed the Biotechs industry which returned 13.8% over the past year.
- IMM underperformed the Market in Australia which returned 2.6% over the past year.
Value
Is Immutep undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Immutep. This is due to cash flow or dividend data being unavailable. The share price is A$0.028.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Immutep's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Immutep's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.01 |
| ASX:IMM Share Price ** | ASX (2019-05-20) in AUD | A$0.03 |
| Global Biotechs Industry PE Ratio | Median Figure of 76 Publicly-Listed Biotechs Companies | 20.25x |
| Australia Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 15.99x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Immutep.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:IMM Share Price ÷ EPS (both in AUD) = 0.03 ÷ -0.01 |
-4.73x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Immutep is loss making, we can't compare its value to the Global Biotechs industry average.
- Immutep is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Immutep's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -4.73x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
80.3%per year |
| Global Biotechs Industry PEG Ratio | Median Figure of 57 Publicly-Listed Biotechs Companies | 1.29x |
| Australia Market PEG Ratio | Median Figure of 359 Publicly-Listed Companies | 1.44x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Immutep, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Immutep's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.01 |
| ASX:IMM Share Price * | ASX (2019-05-20) in AUD | A$0.03 |
| Australia Biotechs Industry PB Ratio | Median Figure of 43 Publicly-Listed Biotechs Companies | 2.97x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.65x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:IMM Share Price ÷ Book Value per Share (both in AUD) = 0.03 ÷ 0.01 |
2.79x |
* Primary Listing of Immutep.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Immutep is good value based on assets compared to the AU Biotechs industry average.
Value checks
We assess Immutep's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Immutep has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Immutep expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Immutep's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Immutep's earnings growth is expected to exceed the Australia market average.
- Immutep's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:IMM Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 80.3% |
| ASX:IMM Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 23.4% |
| Australia Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 10.5% |
| Australia Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 8.8% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.9% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 38 | 7 | 51 | 1 |
| 2022-06-30 | 26 | 0 | 8 | 1 |
| 2021-06-30 | 19 | -6 | -4 | 1 |
| 2020-06-30 | 48 | 23 | -19 | 1 |
| 2019-06-30 | 8 | 56 | -9 | 1 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 5 | -10 | -17 |
| 2018-09-30 | 6 | -9 | -15 |
| 2018-06-30 | 7 | -8 | -13 |
| 2018-03-31 | 6 | -8 | -12 |
| 2017-12-31 | 7 | -8 | -10 |
| 2017-09-30 | 5 | -8 | -9 |
| 2017-06-30 | 4 | -9 | -9 |
| 2017-03-31 | 3 | -8 | -10 |
| 2016-12-31 | 2 | -9 | -10 |
| 2016-09-30 | 2 | -10 | -36 |
| 2016-06-30 | 2 | -11 | -62 |
| 2016-03-31 | 2 | -10 | -71 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from Immutep Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 0.00 | 0.00 | 0.00 | 1.00 |
| 2022-06-30 | 0.00 | 0.00 | 0.00 | 1.00 |
| 2021-06-30 | 0.00 | 0.00 | 0.00 | 1.00 |
| 2020-06-30 | -0.01 | -0.01 | -0.01 | 1.00 |
| 2019-06-30 | 0.00 | 0.00 | 0.00 | 2.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.01 |
| 2018-09-30 | -0.01 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | -0.02 |
| 2016-06-30 | -0.03 |
| 2016-03-31 | -0.04 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Immutep will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Immutep's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Immutep has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Immutep performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Immutep does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Immutep's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Immutep's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Immutep Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 4.90 | -17.10 | 6.50 | |
| 2018-09-30 | 5.88 | -14.92 | 6.87 | |
| 2018-06-30 | 6.85 | -12.75 | 7.24 | |
| 2018-03-31 | 6.37 | -11.61 | 6.58 | |
| 2017-12-31 | 6.76 | -9.63 | 6.23 | |
| 2017-09-30 | 5.44 | -9.50 | 5.29 | |
| 2017-06-30 | 4.12 | -9.37 | 4.35 | |
| 2017-03-31 | 3.49 | -9.81 | 5.20 | |
| 2016-12-31 | 2.09 | -10.06 | 4.92 | |
| 2016-09-30 | 1.93 | -36.04 | 29.68 | |
| 2016-06-30 | 1.76 | -62.02 | 54.45 | |
| 2016-03-31 | 1.65 | -71.37 | 53.98 | |
| 2015-12-31 | 1.43 | -81.77 | 54.34 | |
| 2015-09-30 | 1.38 | -56.96 | 30.03 | |
| 2015-06-30 | 1.34 | -32.15 | 5.72 | |
| 2015-03-31 | 1.39 | -22.97 | 5.32 | |
| 2014-12-31 | 1.45 | -13.79 | 4.91 | |
| 2014-09-30 | 1.73 | -13.57 | 4.50 | |
| 2014-06-30 | 2.02 | -13.34 | 4.09 | |
| 2014-03-31 | 1.96 | -13.25 | 4.39 | |
| 2013-12-31 | 1.90 | -13.15 | 4.69 | |
| 2013-09-30 | 1.78 | -14.19 | 4.77 | |
| 2013-06-30 | 1.65 | -15.23 | 4.85 | |
| 2013-03-31 | 1.58 | -16.94 | 4.96 | |
| 2012-12-31 | 1.52 | -18.66 | 5.07 | |
| 2012-09-30 | 1.52 | -19.30 | 5.52 | |
| 2012-06-30 | 1.52 | -19.94 | 5.98 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Immutep has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Immutep has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Immutep improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Immutep's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Immutep has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Immutep's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Immutep's finances.
The net worth of a company is the difference between its assets and liabilities.
- Immutep is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Immutep's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 4.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Immutep Company Filings, last reported 4 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 33.53 | 7.14 | 26.00 |
| 2018-09-30 | 33.53 | 7.14 | 26.00 |
| 2018-06-30 | 33.52 | 6.65 | 23.48 |
| 2018-03-31 | 33.52 | 6.65 | 23.48 |
| 2017-12-31 | 27.13 | 6.21 | 13.70 |
| 2017-09-30 | 27.13 | 6.21 | 13.70 |
| 2017-06-30 | 26.53 | 5.78 | 12.24 |
| 2017-03-31 | 28.46 | 5.59 | 13.88 |
| 2016-12-31 | 31.25 | 5.40 | 16.57 |
| 2016-09-30 | 31.25 | 5.40 | 16.57 |
| 2016-06-30 | 35.32 | 5.03 | 20.88 |
| 2016-03-31 | |||
| 2015-12-31 | 40.52 | 4.70 | 25.48 |
| 2015-09-30 | 40.52 | 4.70 | 25.48 |
| 2015-06-30 | 24.69 | 1.51 | 6.76 |
| 2015-03-31 | 24.69 | 1.51 | 6.76 |
| 2014-12-31 | 22.97 | 3.50 | 5.73 |
| 2014-09-30 | 22.97 | 3.50 | 5.73 |
| 2014-06-30 | 22.59 | 0.00 | 23.20 |
| 2014-03-31 | 22.59 | 0.00 | 23.20 |
| 2013-12-31 | 30.01 | 0.00 | 28.58 |
| 2013-09-30 | 30.01 | 0.00 | 28.58 |
| 2013-06-30 | 29.25 | 0.00 | 30.02 |
| 2013-03-31 | 29.25 | 0.00 | 30.02 |
| 2012-12-31 | 29.36 | 0.00 | 28.09 |
| 2012-09-30 | 29.36 | 0.00 | 28.09 |
| 2012-06-30 | 37.16 | 0.00 | 38.04 |
- Immutep's level of debt (21.3%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 21.3% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Immutep has sufficient cash runway for 2.6 years based on current free cash flow.
- Immutep has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -3.1% each year.
Financial health checks
We assess Immutep's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Immutep has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Immutep's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Immutep
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Immutep's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Immutep's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 415 Stocks | 4.3% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.6% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | ||
| 2022-06-30 | ||
| 2021-06-30 | ||
| 2020-06-30 | 0.00 | 1.00 |
| 2019-06-30 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Immutep has not reported any payouts.
- Unable to verify if Immutep's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Immutep's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Immutep afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Immutep has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | A$1,339,127 |
| AGE | 45 |
| TENURE AS CEO | 4.8 years |
CEO Bio
Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been the Chief Financial Officer and Chief Operating Officer at caprotec bioanalytics GmbH since joining on July 12, 2011 and serves as its Managing Director. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He serves as the Chief Financial Officer of Immutep Limited since November, 2012 and serves as its Chief Business Officer since May 2012. Mr. Voigt served as a General Manager of The European Operations at Immutep Limited since July 9, 2014. Mr. Voigt has more than 14 years of experience in the corporate and biotechnology sectors. He served as General Manager of German Subsidiary of Immutep Limited since May 2012. He joined Immutep’s management team in 2011 as the General Manager of Prima’s European operations at Prima BioMed GmbH. He has held management positions in a number of biotech and technology investment companies in Europe. He served as Executive Officer of Heidelberger Beteiligungsholding AG. He joined caprotec bioanalytics GmbH from Medical Enzymes AG (New Medical Enzymes AG), where he served as the Chief Financial Officer and Chief Business Officer. He served as the Chief Financial Officer and Chief Business Officer at Revotar Biopharmaceuticals AG. Prior to that, he served as an Investment Manager at Mediport Venture GmbH and Mediport Ventures Fund. Before that, Mr. Voigt worked in business development and managed IPOs for the investment bank net.IPO.AG in Frankfurt. He served as an investment manager for Allianz Insurance biotech venture fund and as a personal assistant to a member of the Executive Board of Allianz Insurance. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings. He served as a Member of the Supervisory Board of Elanix Biotechnologies AG till 2019. He is a Member of the pharma licensing club Germany and a Member of the judging panel of Germany's largest business plan competition. Mr. Voigt earned a Master’s Degree in Business Administration from the Freie Universitat of Berlin.
CEO Compensation
- Marc's compensation has increased whilst company is loss making.
- Marc's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure and age of the Immutep management team in years:
- The tenure for the Immutep management team is about average.
Management Team
Marc Voigt
Executive Director
A$1M
45
4.8 yrs
Deanne Miller
COO, General Counsel & Company Secretary
A$721K
41
2.5 yrs
Frédéric Triebel
Chief Scientific Officer & Chief Medical Officer
A$786K
63
4.4 yrs
Jay Campbell
Chief Business Officer
David Fang
Finance Director & Assistant Company Secretary
1.3 yrs
Board of Directors Tenure
Average tenure and age of the Immutep board of directors in years:
- The average tenure for the Immutep board of directors is less than 3 years, this suggests a new board.
Board of Directors
Russell Howard
Non-Executive Chairman
A$90K
68
1.5 yrs
Marc Voigt
Executive Director
A$1M
45
4.8 yrs
Pete Meyers
Non-Executive Deputy Chairman
A$136K
48
1.5 yrs
Martine Piccart
Chairman of Clinical Advisory Board
1.9 yrs
David Cameron
Member of Clinical Advisory Board
1.9 yrs
Luc Dirix
Member of Clinical Advisory Board
1.9 yrs
Samson Fung
Member of Clinical Advisory Board
1.9 yrs
Salah-Eddin Al-Batran
Member of Clinical Advisory Board
1.9 yrs
Grant Chamberlain
Non-Executive Director
A$138K
47
1.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 02. Oct 18 | Sell | Australian Ethical Investment Ltd | Company | 27. Sep 18 | 28. Sep 18 | -4,028,213 | A$0.05 | A$-186,225 | ||
| 27. Sep 18 | Sell | Australian Ethical Investment Ltd | Company | 04. Sep 18 | 26. Sep 18 | -38,668,280 | A$0.05 | A$-1,618,673 | ||
| 03. Sep 18 | Sell | Australian Ethical Investment Ltd | Company | 25. May 18 | 31. Aug 18 | -10,181,734 | A$0.04 | A$-362,097 | ||
Management checks
We assess Immutep's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Immutep has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Some Immutep (ASX:IMM) Shareholders Are Down 30%
Immutep isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last three years, Immutep saw its revenue grow by 47% per year, compound. … The share price drop of 11% per year over three years would be considered disappointing by many, so you might argue the company is getting little credit for its impressive revenue growth.
Simply Wall St - – Full articleImmutep Limited (ASX:IMM): When Will It Breakeven?
The AU$115m market-cap posted a loss in its most recent financial year of -AU$12.7m and a latest trailing-twelve-month loss of -AU$17.1m leading to an even wider gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for IMM, its year of breakeven and its implied growth rate … Check out our latest analysis for Immutep
Simply Wall St - – Full articleWhy We Think Immutep Limited (ASX:IMM) Could Be Worth Looking At
Help shape the future of investing tools and you could win a $250 gift card! … I've been keeping an eye on Immutep Limited (ASX:IMM) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe IMM has a lot to offer.
Simply Wall St - – Full articleWhat Kind Of Shareholder Appears On The Immutep Limited's (ASX:IMM) Shareholder Register?
The big shareholder groups in Immutep Limited (ASX:IMM) have power over the company. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … With a market capitalization of AU$102m, Immutep is a small cap stock, so it might not be well known by many institutional investors.
Simply Wall St - – Full articleWhy Immutep Limited's (ASX:IMM) Ownership Structure Is Important
I am going to take a deep dive into Immutep Limited’s (ASX:IMM) most recent ownership structure, not a frequent subject of discussion among individual investors. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. … Therefore, it is beneficial for us to examine IMM's ownership structure in more detail.
Simply Wall St - – Full articleImmutep Limited (ASX:IMM): Is Breakeven Near?
With the latest financial year loss of -AU$9.37m and a trailing-twelve month of -AU$9.63m, the AU$108.94m market-cap amplifies its loss by moving further away from its breakeven target? … The most pressing concern for investors is IMM’s path to profitability – when will it breakeven. … Check out our latest analysis for Immutep
Simply Wall St - – Full articleCompany Info
Description
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company’s lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Details
| Name: | Immutep Limited |
| IMM | |
| Exchange: | ASX |
| Founded: | |
| A$101,507,948 | |
| 3,383,598,296 | |
| Website: | http://www.immutep.com |
| Address: |
Immutep Limited 95 Pitt Street, Level 12, Sydney, New South Wales, 2000, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | IMM | Ordinary Shares | Australian Securities Exchange | AU | AUD | 02. Jan 1992 | |
| OTCPK | PRRU.F | Ordinary Shares | Pink Sheets LLC | US | USD | 02. Jan 1992 | |
| DB | YP1B | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 02. Jan 1992 | |
| CHIA | IMM | Ordinary Shares | Chi-X Australia | AU | AUD | 02. Jan 1992 | |
| NasdaqGM | IMMP | SPON ADR EACH REP 100 ORD SHS | Nasdaq Global Market | US | USD | 17. Apr 2012 | |
| DB | YP1A | SPON ADR EACH REP 100 ORD SHS | Deutsche Boerse AG | DE | EUR | 17. Apr 2012 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 10:33 |
| End of day share price update: | 2019/05/20 00:00 |
| Last estimates confirmation: | 2019/04/26 |
| Last earnings filing: | 2019/02/27 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
